Updated on 7 March 2013
Good news for cancer patients who suffer fractures - Dr Reddy's Laboratories launches generic version of Novartis Zometa Injection
Hyderabad: Dr Reddy's Laboratories (DRL) launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Novartis' Zometa (zoledronic acid) 4 mg/5 mL Injection in the US.
The product was launched following the approval by the US Food & Drug Administration (US FDA) of Dr Reddy's Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/5 mL).
Dr Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
